Stelis Biopharma Begins Construction of Multiproduct Biologics Facility at Bioxcell Biotechnology Park, Malaysia
Stelis Biopharma has announced the groundbreaking for construction of its customized, multiproduct, biopharmaceutical manufacturing facility at Bio-Xcell Biotechnology Park in Nusajaya, Johor, Malaysia’s premier park and ecosystem for industrial and healthcare biotechnology.
Stelis Biopharma (a wholly-owned subsidiary of Strides Arcolab) and Bio-XCell had previously announced the signing of a Build and Lease agreement with Bio-XCell for the construction of the building and part of the equipment of Stelis Biopharma’s 140,000 sq. foot biologics facility, for a total project investment amount of RM201 million (USD 60 million).
“Stelis is pleased to commence work on its flagship biopharmaceutical facility in Malaysia. With its strong commitment to bio-economy, attractive incentives, quality infrastructure and enabling ecosystem, we are confident of making this our bio-manufacturing hub for regional and global markets” said Joe Thomas, CEO of Stelis Biopharma, on the occasion.
The construction and fit-out of the facility is expected to be completed in 24 months and commercial operations are targeted to begin mid-2017 at Bio-XCell Park. The 140,000 sq ft facility will incorporate “next-gen” single-use bio-processing technology with both mammalian and microbial manufacturing suites. When complete, it will be one of the few regulated market approvable facilities in the region with end-to-end capability including sterile fill-finish across all formats. The facility will also house an R&D unit to conduct scale-up and process development studies.
“The partnership with Stelis Biopharma to build a multiproduct biologics facility from the start, is seen as a first in Bio-XCell biotechnology Park and timely given the close working relationship over the years. We are happy to see the second biopharma project to commence in Bio-XCell Park and for the facility to ground break over an aggressive construction timeline to see its operations in 2017.It is yet another positive step forward for the park to strengthen the value proposition of the Bio-XCell ecosystem as a regional hub for industrial biomanufacturing and bioprocessing” said Rizatuddin Ramli, CEO of BioXCell Malaysia.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance